PennyMac Financial Services, Inc. Announces Date for Release of Third Quarter 2026 Results
Get Alerts PFSI Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 1.3%
Revenue Growth %: -16.1%
Join SI Premium – FREE
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)-- PennyMac Financial Services, Inc. (NYSE: PFSI) will announce results for the quarter ended September 30, 2026, in a news release to be issued after the market close on Thursday, October 29, 2026. Management will also host a conference call and live audio webcast at 5:00 p.m. Eastern Time to review the results.
The release, webcast, and accompanying materials will be available online at pfsi.pennymac.com. A replay of the webcast will be available shortly after its conclusion.
Individuals who are unable to access the website but would like to receive a copy of the materials should contact our Investor Relations department at 818.264.4907.
About PennyMac Financial Services, Inc.
PennyMac Financial Services, Inc. (NYSE: PFSI) is a national financial services firm focused on the production and servicing of U.S. mortgage loans and the management of mortgage-related investments. Founded in 2008 and headquartered in Westlake Village, California, it is one of the nation's largest mortgage producers and servicers, and one of the few lenders operating at scale across all three production channels. The company combines advanced technology with significant operational scale to serve home buyers, existing homeowners, and its institutional partners nationwide. Additional information about PennyMac Financial Services, Inc. is available at pfsi.pennymac.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261007127822/en/
Media
Kristyn Clark
[email protected]
805.395.9943
Investors
Isaac Garden
[email protected]
818.264.4907
Source: PennyMac Financial Services, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026
- ArriVent Announces Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at ESMO Congress 2026
- Bitcoin News: Tesla-SpaceX Merger Talks Put Their BTC Holdings in Focus as Remittix Plans a 300M RTX Burn
Create E-mail Alert Related Categories
Business Wire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share